Skip to main content
REGN
NASDAQ Life Sciences

Regeneron的Otarmeni基因治疗获得FDA批准用于遗传性听力丧失

feedReported by dpa-AFX
Sentiment info
Positive
Importance info
8
Price
$763.46
Mkt Cap
$80.97B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

美国FDA已为Regeneron的Otarmeni授予加速批准，这是首个用于严重至极度遗传性听力丧失的基因治疗。这个重要的监管里程碑为Regeneron的产品组合添加了一个新的、可能具有高价值的产品，针对一种特定的罕见病况。这一批准是在过去几周Regeneron获得了一系列积极的监管和合作新闻之后。另外，Regeneron宣布了一项与美国政府的协议，以降低当前和未来几种药物的价格，并免费提供Praluent。虽然基因治疗的批准是一个明显的积极因素，但价格协议引入了一个新的、可能具有影响力的因素，影响未来收入和盈利能力，这可能会缓和整体市场反应。交易者将关注Otarmeni的市场潜力和政府价格协议的财务影响细节。

在该公告发布时，REGN的交易价格为$763.46，交易所为NASDAQ，所属行业为Life Sciences，市值约为$809.7亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：dpa-AFX。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article
REGN
Apr 10, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Regeneron Faces Revenue Slowdown, Significant Margin Decline Despite Prior EYLEA HD Approval
Sentiment: Negative
View Wiseek Article